Barclays raises Xeris Biopharma Holdings' target price to $14 from $12
XERS•Barclays raised its target price for Xeris Biopharma Holdings to $14 from $12.
Related News
Nasdaq trade halt continues; reason not available at 03:58 a.m.
MCTA•
Hudbay Minerals: Barclays raises target price to C$46 from C$45
HBM•
VirTra wins five-year CBP contract with up to $14 million potential value
VTSI•
Nasdaq trade halt continues, reason not available at 03:58 am
MAMK•
Stellantis to produce around 450,000 vehicles in Italy in 2026, union says
STLA•